Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 34.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,699 shares of the medical equipment provider’s stock after selling 8,433 shares during the period. Guggenheim Capital LLC’s holdings in Lantheus were worth $1,404,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Portolan Capital Management LLC lifted its holdings in Lantheus by 21.1% in the fourth quarter. Portolan Capital Management LLC now owns 812,630 shares of the medical equipment provider’s stock valued at $72,698,000 after acquiring an additional 141,749 shares during the period. CreativeOne Wealth LLC lifted its stake in shares of Lantheus by 38.9% in the fourth quarter. CreativeOne Wealth LLC now owns 7,175 shares of the medical equipment provider’s stock valued at $642,000 after purchasing an additional 2,008 shares during the period. Synovus Financial Corp boosted its holdings in Lantheus by 13.4% during the fourth quarter. Synovus Financial Corp now owns 25,639 shares of the medical equipment provider’s stock worth $2,294,000 after buying an additional 3,038 shares in the last quarter. Granite Investment Partners LLC grew its position in Lantheus by 3.2% during the fourth quarter. Granite Investment Partners LLC now owns 51,149 shares of the medical equipment provider’s stock worth $4,576,000 after buying an additional 1,579 shares during the period. Finally, Townsquare Capital LLC purchased a new position in Lantheus in the fourth quarter valued at about $1,108,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on LNTH shares. B. Riley lowered their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, March 21st. JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial lifted their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $129.43.

Insider Buying and Selling

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by company insiders.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $100.62 on Tuesday. The company has a market cap of $6.89 billion, a PE ratio of 16.74 and a beta of 0.20. The company has a 50-day simple moving average of $95.76 and a 200-day simple moving average of $95.33. Lantheus Holdings, Inc. has a 12 month low of $62.59 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. On average, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.